PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

This study is testing whether apalutamide — a hormone-blocking drug used for prostate cancer — can improve cancer control and quality of life when added to salvage radiation therapy and standard hormone therapy in men whose PSA has risen after having their prostate surgically removed. **You may be eligible if...** - You have been diagnosed with prostate cancer confirmed by biopsy - Your PSA level has risen to 0.1 or above after prostate removal surgery - Your doctor has recommended salvage radiation and hormone therapy - You are 18 or older - Your general health is good (ECOG performance status 0–2) **You may NOT be eligible if...** - Your organ function or blood counts are below required thresholds - You have serious liver, kidney, or heart conditions that would make treatment unsafe - You are on medications that interact with apalutamide Talk to your doctor to see if this trial is right for you.